Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

United Therapeutics (UTHR) Gross Profit (2016 - 2025)

United Therapeutics' Gross Profit history spans 17 years, with the latest figure at $686.8 million for Q4 2025.

  • For Q4 2025, Gross Profit changed N/A year-over-year to $686.8 million; the TTM value through Dec 2025 reached $2.8 billion, changed N/A, while the annual FY2025 figure was $2.8 billion, 8.98% up from the prior year.
  • Gross Profit for Q4 2025 was $686.8 million at United Therapeutics, down from $698.6 million in the prior quarter.
  • Across five years, Gross Profit topped out at $711.0 million in Q2 2025 and bottomed at -$70.0 million in Q4 2023.
  • The 5-year median for Gross Profit is $478.8 million (2022), against an average of $500.5 million.
  • The largest annual shift saw Gross Profit crashed 116.18% in 2023 before it skyrocketed 33.04% in 2024.
  • A 5-year view of Gross Profit shows it stood at $380.6 million in 2021, then increased by 13.69% to $432.7 million in 2022, then plummeted by 116.18% to -$70.0 million in 2023, then skyrocketed by 1051.14% to $665.8 million in 2024, then increased by 3.15% to $686.8 million in 2025.
  • Per Business Quant, the three most recent readings for UTHR's Gross Profit are $686.8 million (Q4 2025), $698.6 million (Q3 2025), and $711.0 million (Q2 2025).